Local Hyperthermia for the Treatment of Cervical Persistent High-risk Infection
Launched by FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY · Jul 1, 2025
Trial Information
Current as of July 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 18-65 years old; generally healthy gynecological conditions, normal sexual life; high risk HPV for persistent at least 3 months; Cervical biopsy CIN or no cytological changes; signed informed consent
- Exclusion Criteria:
- • Pregnant woman; local or systematic treatment within 3 months; Comorbidity of other severe gynecological inflammation, infection, or tumor; Comorbidity of other serious illnesses; no guarantee of timely treatment and follow-up.
About First Hospital Of China Medical University
The First Hospital of China Medical University is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent sponsor of clinical studies, the hospital leverages its extensive expertise in various medical fields to facilitate the development of new treatments and therapies. Committed to ethical practices and patient safety, the hospital collaborates with a network of researchers and healthcare professionals to ensure rigorous study design and implementation. Its mission is to contribute to the global body of medical knowledge while enhancing the quality of life for patients in China and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shenyang, Liaoning, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported